Search - tctmd.com

Displaying 1 - 20 of 170

Sort: Relevancy | Date

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Conference News EuroPCR 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

Michael O'Riordan

May 28, 2024

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

News Conference News TCT 2022

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients

Yael L. Maxwell

September 27, 2022

News Conference News EuroPCR 2022

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

Caitlin E. Cox

May 25, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

News Conference News TCT 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Michael O'Riordan

November 04, 2021

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Caitlin E. Cox

September 15, 2021

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

L.A. McKeown

May 19, 2021

News Conference News CRT 2021

Polymer-Free Stent Noninferior to ZES at 3 Years: ReCre8

Yael L. Maxwell

March 18, 2021

News Daily News

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

Michael O'Riordan

March 01, 2021

News Daily News

Primary PCI Underused but Just as Effective in Cancer Patients With STEMI

Michael O'Riordan

February 04, 2021

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

News Daily News

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

Michael O'Riordan

July 07, 2020

News Conference News CRT 2020

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

Michael O'Riordan

February 25, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

Advertisement

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

Polymer-Free Stent Noninferior to ZES at 3 Years: ReCre8

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

Primary PCI Underused but Just as Effective in Cancer Patients With STEMI

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content